{
  "documents": [
    {
      "id": "cluster_47_doc1",
      "content": "Pre-authorization form submitted for Gavin T. Wildermuth (Patient ID 487632WQ) regarding neuromodulation implant surgery at Alderwood Neurosciences. Procedure scheduled for April 22, 2024 under policy XG229-884P. Additional documentation required concerning prior denials for nerve ablation treatments in 2023. Contact provider office at 503-847-3391 for clarification.",
      "metadata": {
        "format": "claim_form"
      }
    },
    {
      "id": "cluster_47_doc2",
      "content": "Alderwood Neurosciences quarterly report notes 12% increase in neuromodulation procedures following recent FDA approval. Noteworthy case: G. Wildermuth (DOB 8/15/1978) with refractory neuropathic pain from lumbar disc degeneration responded exceptionally to trial therapy. Research team secured insurance coverage exception after multiple appeals.",
      "metadata": {
        "format": "research_note"
      }
    },
    {
      "id": "cluster_47_doc3",
      "content": "Internal memo regarding policy XG229 revisions effective March 1, 2024: Expanded coverage for neuromodulation devices in patients under 60 with failed conventional therapies. Flags cases meeting new criteria - cross-reference with appeals in processing queue, including account 487632WQ (Wildermuth).",
      "metadata": {
        "format": "insurance_memo"
      }
    },
    {
      "id": "cluster_47_doc4",
      "content": "Quality assurance report for Alderwood Neurosciences highlights complications in 3% of neuromodulation cases. Case review notes excellent recovery for patient residing at 1842 Crestview Lane, correlating with specialized post-op protocol development. Device rep training scheduled April 15, 2024.",
      "metadata": {
        "format": "provider_report"
      }
    },
    {
      "id": "cluster_47_doc5",
      "content": "Patient satisfaction survey from G. Wildermuth rates pain management 9/10 post-implant. Notes challenges navigating prior authorization process despite eventual approval. Suggests clearer timelines for experimental treatment approvals. Contact preference: gw78@protonmail.com.",
      "metadata": {
        "format": "patient_survey"
      }
    },
    {
      "id": "cluster_47_doc6",
      "content": "Portland Tribune health section (April 10, 2024) features breakthrough pain management research at Alderwood Neurosciences. Mentions 45-year-old patient case study who regained functional mobility after novel implant protocol. Quotes lead researcher Dr. Eun-Ji Park on insurance coverage challenges.",
      "metadata": {
        "format": "news_article"
      }
    }
  ],
  "metadata": {
    "category": "cluster",
    "cluster_id": "cluster_47",
    "cluster_risk": "HIGH",
    "content_summary": "Comprehensive documents tracing a patient's neuromodulation implant journey from pre-authorization through post-op outcomes, intersecting with policy changes, research protocols, and media coverage.",
    "person": {
      "entities": [
        [
          "Gavin T. Wildermuth",
          "NAME"
        ],
        [
          "487632WQ",
          "PATIENT_ID"
        ],
        [
          "8/15/1978",
          "BIRTHDATE"
        ],
        [
          "45",
          "AGE"
        ],
        [
          "gw78@protonmail.com",
          "EMAIL"
        ],
        [
          "1842 Crestview Lane",
          "ADDRESS"
        ],
        [
          "lumbar disc degeneration",
          "MEDICAL_CONDITION"
        ],
        [
          "refractory neuropathic pain",
          "MEDICAL_CONDITION"
        ],
        [
          "Alderwood Neurosciences",
          "PROVIDER"
        ],
        [
          "Dr. Eun-Ji Park",
          "PROVIDER"
        ],
        [
          "April 22, 2024",
          "EVENT_DATE"
        ],
        [
          "policy XG229-884P",
          "NON_PERSONAL_ID"
        ],
        [
          "neuromodulation implant surgery",
          "TREATMENT"
        ],
        [
          "nerve ablation treatments",
          "TREATMENT"
        ],
        [
          "trial therapy",
          "TREATMENT"
        ],
        [
          "post-op protocol",
          "TREATMENT"
        ]
      ]
    },
    "questions": [
      {
        "q": "What experimental treatment date and location were approved for Gavin T. Wildermuth's refractory neuropathic pain?",
        "a": "April 22, 2024 at Alderwood Neurosciences.",
        "sources": [
          "cluster_47_doc1"
        ],
        "type": "specific"
      },
      {
        "q": "What policy change in March 2024 affected neuromodulation device approvals?",
        "a": "Expanded coverage for patients under 60 with failed conventional therapies.",
        "sources": [
          "cluster_47_doc3"
        ],
        "type": "general"
      },
      {
        "q": "Which two medical professionals are associated with case ID 487632WQ's treatment and research?",
        "a": "Dr. Eun-Ji Park and the Alderwood Neurosciences team.",
        "sources": [
          "cluster_47_doc2",
          "cluster_47_doc6"
        ],
        "type": "specific"
      },
      {
        "q": "What two developments were reported in April 2024 regarding neuromodulation implant cases?",
        "a": "Specialized recovery protocol development and novel implant protocol coverage challenges.",
        "sources": [
          "cluster_47_doc4",
          "cluster_47_doc6"
        ],
        "type": "general"
      }
    ]
  }
}